SMARTRIOX SIGNED
Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SMARTRIOX project word cloud
Explore the words cloud of the SMARTRIOX project. It provides you a very rough idea of what is the project "SMARTRIOX" about.
Project "SMARTRIOX" data sheet
The following table provides information about the project.
| Coordinator |
TRIOX NANO LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Project website | http://www.smartriox.com |
| Total cost | 2˙847˙667 € |
| EC max contribution | 1˙993˙367 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-06-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | TRIOX NANO LTD | IL (JERUSALEM) | coordinator | 1˙993˙367.00 |
Map
Project objective
Although there are tTriple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2 and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC.
Deliverables
| Project Web page | Websites, patent fillings, videos etc. | 2020-01-14 14:23:12 |
Take a look to the deliverables list in detail: detailed list of SMARTRIOX deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMARTRIOX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SMARTRIOX" are provided by the European Opendata Portal: CORDIS opendata.